SIPP-432 research has demonstrated induction of delta (slow-wave) sleep and associated growth hormone release, reduction of stress hormone (corticotropin) levels, and broad stress-protective or adaptogenic effects. SIPP also exhibits neuroprotective properties, improving outcomes in ischemic brain injury and reducing oxidative stress in the central nervous system. The formulation comprises Magnolia officinalis, Valeriana officinalis (valerian), Passiflora incarnata (passionflower), Withania somnifera (ashwagandha), Ziziphus spinosa (jujube seed), Scutellaria lateriflora (skullcap), Apocynum venetum (Luobuma), and L-theanine
